| Hillhouse Fund IV (Hillhouse Capital) | $10,600 | Hillhouse plans to invest in companies focused on healthcare, consumer, technology and services sectors globally, although mostly in Asia. It has made investment in well-known companies like search engine Baidu, AirBnB and Uber Technologies. | Undisclosed | Fundraising | Hong Kong |
| KKR | $7,400 | KKR has a risk-based, rather than a sector-based, approach to infrastructure investing. KKR will be investing $358 million (KKR Global Infrastructure Fund) alongside external investors through KKR’s balance sheet and employee commitments. | Undisclosed | Fundraising | United States |
| Mazor Robotics | $1,640 | Medtronic’s acquisition of Mazor strengthens Medtronic’s position as a global leader in enabling technologies for spine surgery, and drives Mazor Robotics’ vision towards the global market. Mazor‘s proprietary core platforms include the Mazor X™ Robotic Guidance System and the Renaissance® Surgical-Guidance System. | Medtronic | Acquisition | Israel |
| Elanco Animal Health (Eli Lilly and Company) | $1,510 | The offering is expected to represent an ownership stake of less than 20 percent in Elanco. The number of shares to be offered and the price range for the offering have not yet been determined. The company expects to complete the IPO process before the end of 2018. | Goldman Sachs | IPO | United States |
| Syntimmune | $1,200 | Syntimmune's lead candidate, SYNT001, is a humanized monoclonal antibody that inhibits the interaction of FcRn with Immunoglobulin G (IgG) and IgG immune complexes in a number of rare IgG-mediated diseases. SYNT001 is currently being evaluated in Phase 1b/2a studies in warm autoimmune hemolytic anemia and pemphigus vulgaris. | Alexion Pharmaceuticals | Acquisition | United States |
| Sandoz US | $1,000 | Aurobindo Pharma USA will acquire selected portions of Novartis' Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio. The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, the Sandoz US generic and branded dermatology businesses, Sandoz' dermatology development center and the manufacturing facilities in Wilson, NC, as well as Hicksville and Melville, NY. | Aurobindo Pharma USA | Acquisition | United States |
| Oberland Capital | $800 | Fund II will target investments between $20 million and $150 million with a focus on commercial stage or near-commercial stage biopharmaceutical, medical device and diagnostic companies and royalty-bearing products. | Undisclosed | Fundraising | United States |
| Regeneron R&D Manufacturing Facility | $800 | Regeneron Pharmaceuticals will invest $800 million and hire an additional 1,500 employees in East Greenbush, New York, as the drug maker increases production over the next seven years. The expansion plans will include construction of 350,000 square feet of manufacturing space and 240,000 square feet of office and laboratory space. | Regeneron Pharmaceuticals | Manufacturing Investment | United States |
| Tusk Therapeutics, Droia Oncology Ventures | $655 | Tusk was founded in 2014 by Droia Oncology Ventures, Tusk’s majority shareholder. Under the terms of the agreement, Tusk’s shareholders will receive an upfront cash payment of Euro 70 million, plus additional contingent payments of up to Euro 585 million based on achievements of certain predetermined milestones. | Roche | Acquisition | United Kingdom |
| Vivo Opportunity Fund | $635 | As a long-only public equity fund, the Fund plans to invest the capital in small to mid-cap public life sciences companies through follow-on financings, private placements, initial public offerings to be invested in private and public therapeutics companies. The Fund is focused on investing in companies bringing innovative products to the market. | Vivo Capital | Fundraising | United States |
| Siga Technologies | $629 | Siga has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA) for the delivery of oral and intravenous (IV) formulations of TPOXX® to the Strategic National Stockpile. The contract also covers advanced development of the IV formulation and post-marketing activities. | Biomedical Advanced Research & Development Authority | Contract Agreement | United States |
| Augmenix | $600 | Acquisition expands portfolio of men's health in-office procedures with adjunctive therapy for prostate cancer patients: The SpaceOAR hydrogel is CE Marked, cleared by the FDA and has been used in more than 30,000 patients worldwide. As a result of commercial adoption, expanded U.S. reimbursement and a total addressable market valued at $750 million, product sales are estimated to reach $50 million in 2018, and approach $90 million in 2019. | Boston Scientific | Acquisition | United States |
| Novartis | $463 | Mylan closed an agreement with Novartis to purchase the worldwide rights to commercialize their global cystic fibrosis products consisting of TOBI Podhaler® and TOBI® solution, which will further enhance Mylan’s respiratory portfolio in the U.S., Europe and certain RoW markets. | Mylan | Commercialization Agreement | Switzerland |
| Nationwide Children’s Hospital and The Ohio State University, Celenex | $452 | The ten programs are licensed to Amicus from Nationwide Children’s Hospital through the acquisition of Celenex, a private, clinical stage gene therapy company. The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devastating diseases. | Amicus Therapeutics, BioPharma Credit | Portfolio Acquisition | United States |
| Xynomic Pharmaceuticals | $450 | Xynomic will merge into Bison Capital Merger Sub Inc with Xynomic continuing as the surviving company. Xynomic focuses on orally delivered small molecule drugs in oncology through both in-licensing from strategic partners supported by its scientists with expertise in tyrosine kinase inhibition and epigenetic modification. | Bison Capital Acquisition Corp. | Merger Agreement | China |
| Precision BioSciences | $445 | Precision will be primarily responsible for the development, formulation, and preclinical evaluation of the investigational nucleases, and Gilead will be responsible for the clinical development and commercialization of potential therapies. | Gilead Sciences | Collaboration | United States |
| IbexTM Design, IbexTM Develop | $403 | The two new IbexTM Solutions, IbexTM Design and IbexTM Develop, announced today are designed to meet the evolving needs of biotech companies with antibodyntherapies, from the preclinical stage through to commercialization. | Lonza | Manufacturing Investment | Switzerland |
| Teva Pharmaceutical Industries | $400 | Teva is engaging in the Offers to reduce its total debt and decrease its overall interest expense. Teva expects to fund the Offers with available cash on hand. | Undisclosed | Senior Notes Offering | Israel |
| Lung Biotechnology PBC (United Therapeutics) | $340 | SM04646, a Wnt pathway inhibitor, is currently undergoing a phase 1 clinical trial. Under the terms of the agreement, United Therapeutics' subsidiary, Lung Biotechnology PBC, will conduct and fund all further development, regulatory and commercialization activities in the U.S. and Canada. | Samumed | Licensing Agreement | United States |
| Molecular Template | $338 | Takeda and Molecular Templates will further develop the ETBs for the treatment of multiple myeloma under this new license, development and commercialization agreement. Molecular Template's developed CD38-targeted ETBs recognize the protein and deliver a modified bacterial toxin that enters the myeloma cells and destroys them through the enzymatic and irreversible destruction of ribosomes. | Takeda Pharmaceutical Company Limited | Commercialization Agreement | United States |
| Inaugural Fund | $320 | The founding team will include industry veterans and managing directors, Beth Seidenberg, M.D. – general partner at Kleiner Perkins and former chief medical officer and head of global development at Amgen – and Sean Harper, M.D., executive vice president and head of R&D at Amgen who will move to the firm in January 2019. | Westlake Village BioPartners | Fundraising | United States |
| Life Healthcare Group Holdings | $293 | Life Healthcare, one of South Africa’s largest private healthcare providers, announced it has accepted an offer from KKR to acquire its 49.7% stake in Max Healthcare Institute Limited. KKR is a leading global investment firm that manages multiple alternative asset classes. | KKR | Acquisition | South Africa |
| Velo Bio | $288 | AMAG Pharmaceuticals has acquired global rights to develop and market digoxin immune Fab (ovine) (DIF), a polyclonal antibody in development for the treatment of severe preeclampsia in pregnant women. | AMAG Pharmaceuticals | Option Agreement | United States |
| NHS England | $258 | The Government is planning to make more than £200 million available to a group of NHS trusts to boost the development of digital technology for healthcare, along with the publication of new standards to promote the interoperability of systems. | Government of UK | Fundraising | United Kingdom |
| ACEA Biosciences | $250.00 | ACEA Biosciences is a company known for developing highly innovative products, which are used in academia, as well as the biotech and pharmaceutical industries. In recent years, the ACEA xCELLigence® RTCA technology has blazed a trail in immuno-oncology, pre-clinical drug discovery and development, as well as in basic academic research. | Agilent Technologies | Acquisition | United States |
| Butterfly Network | $250 | The new device, named Butterfly iQ, was inspired by Rothberg's own personal experiences. His daughter was born with a disease called tuberous sclerosis, which creates tiny tumors all over the body. The treatment procedure for this requires the use of a high-frequency ultrasound and MRI-imaging. | Fidelity Investments | Series D Financing | United States |
| ViraTherapeutics, EMBL Ventures | $245 | VSV-GP is a highly potent oncolytic virus, which leads to an enhanced immune response that works together with the direct viral anti-tumour effect. ViraTherapeutics' lead candidate leverages the VSV-GP platform, a next generation oncolytic viral therapy, which has shown promising results in pre-clinical models, especially in combination with key immune modulatory principles. | Boehringer Ingelheim | Acquisition | Austria |
| Zealand Pharma | $205 | “The licensing agreement with Sanofi has provided Zealand significant funding since 2003. However, since we do not have influence on the commercialization, nor visibility over future revenue, the monetization provides financial certainty and independence,” added Mats Blom, Executive Vice President and Chief Financial Officer at Zealand. | Royalty Pharma, Sanofi | Royalty Transaction | Denmark |
| Alvotech | $200 | This collaboration aligns the interests and strengths of Alvotech and CCHN, where a new state-of-the-art biologics drugs manufacturing facility will be built in Changchun, China. | Changchun High & New Technology | Joint Venture | Iceland |
| Alachua-Florida Facility | $200 | Brammer is conducting a further expansion of its first commercial facility, located in Cambridge, Mass., increasing the number of commercial suites from 7 to 12, supporting up to 2,000-liter suspension and adherent processes. Construction of this additional capacity will be completed in the first half of 2019. | Brammer Bio | Fundraising | United States |
| Bonti | $195 | Following completion of the acquisition, Allergan will obtain global rights to Bonti's pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development, EB-001A (aesthetic) and EB-001T (therapeutic). The active ingredient in both programs, EB-001, is a novel botulinum neurotoxin serotype E (BoNT/E). | Allergan plc | Acquisition | United States |
| Invuity | $190 | "The combination of Stryker's established leadership in minimal access surgery paired with Invuity’s suite of enabling visualization and surgical devices should facilitate better patient outcomes and operating room efficiencies in women’s health, general surgery, electrophysiology and orthopedics," said Scott Flora, Invuity’s Interim Chief Executive Officer. | Stryker Corporation | Acquisition | United States |
| Biscayne Neurotherapeutics | $183 | Supernus will obtain worldwide rights (excluding certain markets in Asia where rights have been out-licensed) to Biscayne’s product candidate. The development program which will be referred to as SPN-817 will utilize a novel synthetic form of huperzine A which is a potent acetyl cholinesterase inhibitor with pharmacological activities in CNS conditions such as epilepsy. SPN-817 will have a new chemical entity status (NCE) in the U.S. market. | Supernus Pharmaceuticals | Acquisition | United States |
| Viking Therapeutics | $176 | Viking currently intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development | William Blair & Company | IPO | United States |
| Endocyte | $175 | Endocyte intends to use the net proceeds from the proposed offering, if completed, to fund the continued clinical development of its pipeline products and preparation for the commercial launch of 177Lu-PSMA-617, if approved, as well as for working capital. | Undisclosed | IPO | United States |
| Galera Therapeutics | $150.00 | Galera plans to use the proceeds of the combined equity and royalty financings to advance the clinical development of GC4419 into and through a pivotal Phase 3 clinical trial for the treatment of severe oral mucositis (SOM) in patients with head and neck cancer. | Clarus | Series C Financing | United States |
| Fate Therapeutics | $144 | Fate Therapeutics intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies, the manufacture of clinical product candidates and the conduct of preclinical research and development. | Jefferies, Piper Jaffray | IPO | United States |
| Urovant Sciences | $140 | Urovant’s lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. | J.P. Morgan | IPO | Switzerland |
| Jianke Pharmaceutical | $130 | Jianke is the largest online B2C pharmacy in China, offering 680,000 SKUs and a robust set of healthcare advisory services. Jianke leads its competitors in terms of brand name recognition, number of users, user acquisition costs, product & service offerings, and online traffic as measured by Alexa indexes. | HBM Healthcare Investments, GTJA Investment Group | Series B Financing | China |
| Atreca | $125 | This first candidate, generated by the company's unique Discovery Engine and through its proprietary Immune Repertoire Capture (IRC™) technology, represents a new potentially fundamental new class of oncology immunotherapeutics. Atreca is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications. | Wellington Management Company | Series C Financing | United States |
| Focal Therapeutics | $125 | Focal generated approximately $16 million of revenue in the last 12 months. The acquisition, which is expected to close in early October, is estimated to be neutral to Hologic’s non-GAAP earnings per share in fiscal 2019, and accretive thereafter. | Hologic | Acquisition | United States |
| Allogene Therapeutics | $120 | Allogene is advancing its allogeneic CAR T cell portfolio, which includes rights to 16 preclinical CAR T cell therapy targets and U.S. rights to UCART19, an allogeneic CAR T cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. | Cowen Group | Private Financing | United States |
| Arvinas | $120 | Arvinas is focused on the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. | Goldman Sachs | IPO | United States |
| Hua Medicine | $110 | Shanghai-based Hua Medicine is a leading, innovative development company, currently focused on developing a global first-in-class oral drug, Dorzagliatin or HMS5552, for the treatment of Type 2 diabetes, and mGLUR5, a potential novel drug candidate for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). | Goldman Sachs (Asia) L.L.C. | IPO | China |
| Aralez Pharmaceuticals | $110 | Assuming completion of the Transaction, Nuvo would acquire Aralez's Canadian specialty-pharmaceutical business, which was formerly known as Tribute Pharmaceuticals Canada Inc. (Tribute). This is a growing business that includes Cambia®, BlextenTM, SuvexxTM / Treximet® in the U.S. | Nuvo Pharmaceuticals, Deerfield | Acquisition | Canada |
| Principia Biopharma | $106 | Principia Biopharma, which is developing oral small molecule therapies for pemphigus, immune thrombocytopenic purpura and MS, raised $106 million by offering 6.3 million shares at $17, the high end of the range of $15 to $17. Insiders intend to purchase up to $26 million of the IPO (25% of the deal). | Undisclosed | IPO | United States |
| 111, Inc. (New Peak Group) | $101 | The company intends to use about US$50.8 million of the net proceeds for selling and marketing to expand its customer base and another US$ 38.1 million will be allocated to research and development, and invest in technologies such as artificial intelligence, big data, and cloud-based solutions. | Undisclosed | IPO | China |
| Adaptimmune Therapeutics | $100 | Net proceeds of the offering will be used to advance the company’s wholly owned pipeline of SPEAR T-cell candidates through clinical trials as well as for other general corporate purposes. | Matrix Capital | IPO | United Kingdom |
| Dicerna Pharmaceuticals | $100 | Dicerna intends to use the net proceeds from this offering for preclinical studies and clinical trials, and to use the remainder of any net proceeds for continued technology platform development, working capital and general corporate purposes. | H.C. Wainwright & Co. | IPO | United States |
| HLS Therapeutics | $100 | HLS Therapeutics is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets focused on indications in the Central Nervous System and Cardiovascular segment. | Silicon Valley Bank | Fundraising | Canada |
| Allogene Therapeutics | $100 | Allogene Therapeutics, with headquarters in South San Francisco, is a clinical stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (CAR T) therapies for cancer. | Goldman Sachs | IPO | United States |
| Osmotica Pharmaceuticals | $100 | Osmotica Pharmaceuticals develops and sells branded and generic pharmaceutical products. Osmotica develops, manufactures, and sells specialty products using its controlled release technologies; currently it is developing branded treatments for muscle spasticity and droopy eyelid. | Undisclosed | IPO | United States |
| Gritstone Oncology | $100 | Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - Gritstone EDGE™ and the ability to develop and manufacture potent immunotherapies using tumor-specific neoantigens. | Goldman Sachs | IPO | United States |
| Y-mAbs Therapeutics | $96 | Y-mAbs Therapeutics, a phase 2 biotech developing monoclonal antibody therapies for pediatric cancers. YMAB has a strong collaboration partnership with the Memorial Sloan Kettering Cancer Center and top tier investors. | Bank of America Merrill Lynch | IPO | United States |
| MannKind Corporation | $95 | United Therapeutics will be responsible for global development, regulatory and commercial activities with regard to the development and commercialization of a dry powder formulation of treprostinil currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. | United Therapeutics Corporation | Licensing Agreement | United States |
| 4D Molecular Therapeutics | $90 | The proceeds from this financing will be used to advance its proprietary Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics. The company’s lead intravitreally-delivered AAV gene therapy asset for choroideremia is expected to enter clinical trials in 2019. | Viking Global Investors | Series B Financing | United States |
| Kodiak Sciences | $90 | Kodiak Sciences is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases. It raised $90 million in the IPO. The company had a net loss of $27.9 million and no revenue in 2017, compared with a loss of $17.1 million and no revenue in 2016. | Morgan Stanley | IPO | United States |
| LogicBio Therapeutics | $86 | LogicBio Therapeutics is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical needs using GeneRide™, its proprietary technology platform. GeneRide™ enables the site-specific integration of a therapeutic transgene, in a nuclease-free and promotorless approach by relying on the native process of homologous recombination to drive lifelong expression. | Undisclosed | IPO | United States |
| Sutro Biopharma | $85 | Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF™, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders, today announced the pricing of its initial public offering of 5,667,000 shares of its common stock at a price to the public of $15.00 per share. | Cowen | IPO | United States |
| ChemoCentryx, GlaxoSmithKline | $85 | The increased investment follows the establishment of a partnership with ChemoCentryx since May 2016. Under the terms of the current in-licensing agreements, Vifor Pharma Group has the exclusive rights to commercialize avacopan and CCX140 for orphan and rare renal diseases in all markets outside of the United States. | Vifor Pharma Group | Equity Investment | Switzerland |
| uBiome | $83 | uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. The Company’s commercial products include SmartGut™, a doctor-ordered stool test that identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease and ulcerative colitis. | 8VC, Y Combinator | Series C Financing | United States |
| Fulcrum Therapeutics | $80 | Fulcrum is pioneering a small molecule, precision medicine approach to address serious monogenic and prevalent diseases of gene misregulation. The proceeds from the financing will be used to advance Fulcrum’s lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for rare, genetically-based neuromuscular, central nervous system and hematologic disorders. | Foresite Capital | Series B Financing | United States |
| Morphic Therapeutic | $80 | To fund its two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic. | Omega Funds, Novo Holdings | Series B Financing | United States |
| KSQ Therapeutics | $80 | KSQ will advance its first drug program into the clinic within the next 18 months and up to three additional oncology drug programs into IND-enabling studies. The company’s first drug program is a modified adoptive T-cell immunotherapy which has shown efficacy in multiple animal models of PD-1 resistance. | Baillie Gifford | Series C Financing | United States |
| Shield Therapeutics | $79 | This long-term exclusive licence grants Norgine the right to commercialise Feraccru® in the UK, France, Germany, Italy, Spain and all other European countries which are not already covered by Shield’s previously announced licence agreements with AOP Orphan Pharmaceuticals AG and Ewopharma AG, as well as in Australia and New Zealand (the “Licensed Territories”). | Norgine B.V. | Licensing Agreement | United Kingdom |
| Principia Biopharma | $75 | Principia Biopharma is developing oral small molecule therapies in the areas of oncology and immunology. The company plans to use $50 million of the stock offering’s proceeds to complete mid-stage studies for its lead drug candidate, PRN1008, and advance it into Phase 3 testing. | Bank of America Merrill Lynch | IPO | United States |
| Entasis Therapeutics | $75 | The firm is advancing a pipeline of drug candidates for the treatment of various antibiotic-resistant infections. The company’s lead product candidate ETX2514, as well as one of their other product candidates, ETX0282 are B-Lactamase Enzymes inhibitors [BLIS]. Their name originates from their ability to inactivate B-Lactam antibiotics, one of the most commonly used classes of antibiotics. | Credit Suisse | IPO | United States |
| Aldeyra Therapeutics | $72 | Aldeyra anticipates using the net proceeds from the offering for the continued development of Aldeyra's lead compound reproxalap and other product candidates, as well as for debt maintenance, working capital, and other general corporate purposes. | Citigroup | IPO | United States |
| MeMed | $70 | MeMed will use the proceeds to advance in three areas: (i) Market adoption of MeMed BV™; (ii) Complete development, upscale manufacturing and clearance of MeMed Key™, a pioneering point-of-care protein measurement platform; and (iii) Expand its pipeline of immune-based measurements to tackle big clinical challenges. | Ping An Global Voyager Fund | Fundraising | Israel |
| Twentyeight-Seven Therapeutics | $65 | 28-7’s initial focus is on modulating miRNAs, which are short ncRNAs that inhibit target gene expression by suppressing mRNA translation and/or promoting mRNA decay. It is now well recognized that miRNAs are directly involved in cancer initiation, progression, and metastasis. | MPM Capital | Series A Financing | United States |
| Mithra Pharmaceuticals | $64 | Estelle is a combined oral contraceptive containing 15 mg estetrol (E4) and 3 mg drospirenone. | Gedeon Richter | Licensing Agreement | Belgium |
| KalVista Pharmaceuticals | $64 | KalVista intends to use the net proceeds from this offering to fund late-stage development of KVD900, including beyond anticipated Phase 3 data and a potential larger Phase 2 trial for a new drug application and new hereditary angioedema (HAE) and oral diabetic macular edema (DME) programs. | Undisclosed | IPO | United States |
| Valneva SE | $58 | The offering proceeds raised will be used to pursue the clinical development of the Company's pipeline candidates, notably its vaccine candidates against Lyme and Chikungunya. | Groupe Grimaud | Oversubscribed Placement | France |
| Clarify Health | $57 | Clarify's team has a track record of achieving over $1 billion in improvement at more than 125 health systems, payers, and pharmaceutical companies. | KKR | Series B Financing | United States |
| Valeant Pharmaceuticals (Bausch Health Companies) | $53 | Xenon Pharmaceuticals' agreement with Valeant is aimed to buy out all milestone payments and royalties with respect to XEN1101, which is a Kv7 potassium channel opener being developed by Xenon for the treatment of epilepsy. | Xenon Pharmaceuticals | Royalty Payment Buyout | Canada |
| Tianjin Tasly Pharma | $50 | According to data from the phase-two clinical study of T89, the change of Total Exercise Duration (TED), the gold endpoint in clinical trials of T89 for the prevention and treatment of recurrence of stable angina pectoris, is of both statistical and clinical significance. | Arbor Pharmaceuticals | Research & Development Agreement | China |
| Chugai Pharmaceutical (Roche Group) | $50 | OWL833 is Chugai’s oral non-peptidic GLP-1 receptor agonist. OWL833 is a Phase 1-ready asset that is being studied for the treatment of type 2 diabetes. Lilly will receive worldwide development and commercialization rights to OWL833. | Eli Lilly | Licensing Agreement | Japan |
| CASI Pharmaceuticals | $48.5 | CASI intends to use the net proceeds from the offering principally to support a broad and evolving platform, including its in-licensed products, EVOMELA®, MARQIBO® and ZEVALIN®, are all currently in various regulatory stages for market approval in China. | Undisclosed | Private Placement | United States |
| Silverback Therapeutics | $47.5 | Silverback's proprietary ImmunoTAC technology and integrated R&D approach enables the design of product candidates that can be administered systemically, but that act only at the sites of disease. The approach is designed to spare healthy tissues from unwanted side effects, while modifying disease processes in a potent and targeted manner. | OrbiMed | Series A Financing | United States |
| Medexus | $46 | Combining Pediapharm’s Canadian pediatric speciality pharmaceutical business with the Canadian diversified speciality pharmaceutical business and rheumatology speciality pharmaceutical business of Medac Pharma, the Acquisitions will create a leading North American commercial-stage specialty pharmaceutical company. | Pediapharm | Acquisition | Canada |
| Evox Therapeutics | $45 | Proceeds from this financing will support the advancement of Evox's exosome-based therapeutics pipeline, including progression of several proprietary rare disease assets towards the clinic, and continued development of its world-leading exosome drug platform. | Redmile Group | Series B Financing | United Kingdom |
| Molecular Template | $45 | Molecular intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund: its ongoing Phase Ib and Phase II clinical studies and planned additional Phase II clinical studies for MT-3724 in DLBCL; its share of development expenses in its CD38 collaboration with Takeda; its programs targeting HER2 and PD-L1 | UBS Group AG | IPO | United States |
| Verastem Oncology | $45 | COPIKTRA also received accelerated approval for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. | CSPC Pharmaceutical Group Limited | Commercialization Agreement | United States |
| IDA Ireland | $43 | The Drug Product Filling Project investment estimated at approximately $43 million, which is projected to create an additional 51 roles across all disciplines, will augment the site’s Drug Substance Manufacturing and Secondary Packaging and Labelling capability. | BioMarin | Manufacturing Investment | Ireland |
| OncoResponse | $40 | The proceeds will be used to advance the company’s five drug candidates into preclinical and clinical development. All drug candidates were derived from OncoResponse’s discovery platform, which mines the immune systems of patients who have responded exceptionally well to cancer immunotherapies. | RiverVest Venture Partners | Series B Financing | United States |
| Fullerton Health Philippines Pte Ltd (Fullerton Healthcare Corporation) | $40 | The IFC investment will help improve the provision of affordable, quality healthcare in the Philippines and enhance efficiencies in the health maintenance organisation ("HMO") market through increased integration between the financing and provision of healthcare. | International Finance Corporation | Fundraising | Philippines |
| Nicox SA | $40 | Naproxcinod, a Cyclooxygenase-Inhibiting Nitric Oxide (NO)-Donating (CINOD) naproxen, is a non-steroidal anti-inflammatory product candidate originally discovered and developed by Nicox. A broad clinical package already exists for naproxcinod in osteoarthritis, including three phase 3 studies with over 2,700 patients. | Fera Pharmaceuticals | Development Agreement Amendment | France |
| Cellular Biomedicine Group | $40 | "This collaboration with Novartis reflects our shared commitment to bringing the first marketed CAR-T cell therapy Kymriah, a transformative treatment option currently approved in the United States, European Union and Canada for two difficult-to-treat cancers, to China where the number of patients in need remains the highest in the world," said Tony Liu, Chief Executive Officer, CBMG. | Novartis | Licensing Agreement | China |
| Valneva SE | $40 | The offering proceeds, amounting to €37.7 million, raised will be used to pursue the clinical development of the Company's pipeline candidates, notably its vaccine candidates against Lyme and Chikungunya. | Guggenheim Securities | Private Placement | France |
| Fundación Científica de la Asociación Española Contra el Cáncer, Associazione Italiana per la Ricerca sul Cancro | $40 | In partnership with the leading cancer research charities in Spain and Italy, Cancer Research UK is building international research networks to forge new scientific collaborations in the fight against cancer. The Accelerator Award supports cross-institutional collaborations across a wide range of research areas, including pre-clinical studies, biomarkers, imaging, radiotherapies, engineering, physical sciences and many others. | Cancer Research UK | Grants & Awards | Italy |
| Ceribell | $35 | Ceribell raised $35 million to fund commercialization of its rapid response EEG system, which can quickly diagnose patients suspected of having nonconvulsive seizures with no visual symptoms, for use in neurological intensive care units and emergency rooms. | Optimas Capital Partners Fund | Series B Financing | United States |
| PhaseBio | $34 | PhaseBio plans to use the proceeds from the Series D financing to advance the clinical development of its lead product candidate PB2452. Additionally, the company plans to initiate a Phase 2 clinical study of its ELP-based therapy PB1046 in pulmonary arterial hypertension in the third quarter of 2018. | AstraZeneca | Series D Financing | United States |
| Immune-Onc Therapeutics | $33 | “As we prepare to move from translational research into the clinic, Adrian and An’s decades of industry expertise in drug development will be critical in advancing our mission to develop novel biotherapeutics for hard-to-treat cancers,” said Charlene Liao, Ph.D., co-founder, president and chief executive officer of Immune-Onc Therapeutics. | Northern Light Venture Capital | Series B Financing | United States |
| IDX | $33 | The company's first diagnostic system, IDx-DR, is the only AI system cleared by the FDA to detect diabetic retinopathy without requiring a clinician to interpret the image or results. This enables health care providers who are not normally involved in eye care to use the AI system to test for this leading cause of blindness during routine office visits. | 8VC | Fundraising | United States |
| Immune-Onc Therapeutics | $33 | Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. | Northern Light Venture Capital | Series B Financing | United States |
| Civica Rx | $30 | Civica Rx has identified 14 hospital-administered generic drugs as its initial focus, seeking to stabilize the supply of essential medications, many of which have fallen into chronic shortage situations. The company expects to release its first products as early as 2019. | Laura and John Arnold Foundation, Peterson Center on Healthcare, Gary and Mary West Foundation | Launch | United States |
| Akrevia Therapeutics | $30 | Akrevia’s Aklusion platform allows potently active biological molecules to be inactive until they encounter the tumor microenvironment. With a potential best-in-class anti-CTLA4 antibody as validation, the technology can be applied broadly to highly-potent cytokines and chemokines which currently have limited or no clinical utility due to toxicities. | F-Prime Capital Partners | Series A Financing | United States |
| Lyra Therapeutics | $30 | The Series B financing provides Lyra with the funding for the planned Phase 2 study of LYR-210 in chronic rhinosinusitis (CRS), a debilitating disease caused by inflammation of the paranasal sinus tissues. | Perceptive Advisors | Series B Financing | United States |
| Alpha Tau Medical | $29 | Alpha DaRT (D?ffus?ng Alpha-em?tters Rad?at?on Therapy) enables the first alpha-radiation-based cancer treatment for various types of solid tumors. The company has started clinical trials with leading research centers throughout the world to investigate Alpha DaRT as a treatment for cancer using different protocols across a variety of indications, including Pancreatic, Breast, Head and neck, Prostate and Gynecological cancer | Shavit Capital | Private Placement | Israel |
| Ichorion Therapeutics | $26.6 | Ichorion has established a unique pipeline which augments the existing neurology assets in Cerecor’s pipeline, adding multiple substrate replacement therapies with the potential to leverage the 505(b)(2) pathway to accelerate development and approval. | Cerecor | Acquisition | United States |
| ViaCyte | $25 | ViaCyte’s lead product candidate "PEC-Direct" is currently being evaluated clinically. PEC-Direct is being developed as a therapy for the subset of patients with type 1 diabetes at high risk for acute complications. | CRISPR Therapeutics | Collaboration | United States |
| Minoryx Therapeutics | $24.45 | MIN-102 is a novel, orally bioavailable and selective PPAR gamma agonist with a superior profile for central nervous system-related diseases. It is currently in a phase 2/3 clinical trial for the treatment of adrenomyeloneuropathy. | SFPI-FPIM | Series B Financing | Spain |
| Xylaze (PharmaMar Group) | $21.8 | PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. | AkzoNobel | Divestment | Spain |
| Novate Medical | $20 | Novate has developed Sentry, the first bioconvertible inferior vena cava (IVC) filter, which has recently been granted 510(k) regulatory clearance in the US. | BTG | Acquisition | Ireland |
| Biodesy | $20 | Biodesy is using the proceeds to expand its scientific and commercial operations team, demonstrate further value in the discovery and development of novel therapeutics, and leverage its core technology via strategic partnerships. The new CEO appointment and financing round will enable the company to drive biopharmaceutical adoption of its technology platform. | Alexandria Venture Investments | Series C Financing | United States |
| Coda Biotherapeutics | $19 | CODA’s chemogenetic platform aims to control the activity of neurons and other cells to treat diseases. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. | MPM Capital | Series A Financing | United States |
| Cancer Research UK City of London Centre | $18.3 | The new Cancer Research UK City of London Centre* brings together world-leading researchers from UCL, King’s College London, Queen Mary University of London and the Francis Crick Institute. It will become a global centre of excellence for biotherapeutics, a pioneering field of cancer research. | Cancer Research UK | Fundraising | United Kingdom |
| China SXT Pharmaceuticals | $17 | China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces. | Boustead Securities | IPO | China |
| Novocure | $15 | Zai Lab granted license to commercialize oncology platform technology Tumor Treating Fields, including the brand name Optune®, in China, Hong Kong, Macau and Taiwan. Optune (Tumor Treating Fields) currently marketed in the U.S., the EU and Japan for the treatment of glioblastoma and in advanced clinical development for multiple solid tumor indications | Zai Lab | Licensing Agreement | United States |
| Agenus | $15 | Agenus, an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies, today announced the closing of its non-dilutive royalty transaction with XOMA Corporation (XOMA), where XOMA purchased a minority interest in the royalties and milestones that Agenus is eligible to receive from Incyte and Merck. | XOMA Corporation | Royalty Transaction | United States |
| Medical Aesthetics Innovation Center | $15 | The Medical Aesthetics Innovation Center to be located at the High-Tech Zone of Chengdu, will feature a world-class training center for medical aesthetics healthcare professionals, as well as an education and product experience center for medical aesthetics consumers. | Allergan plc | Cooperation Agreement | China |
| Janssen Vaccines & Prevention B.V., The Jenner Institute | $15 | New collaboration with Coalition for Epidemic Preparedness Innovations (CEPI) and The Jenner Institute is latest example of Johnson & Johnson’s ongoing commitment to global pandemic preparedness efforts | Coalition for Epidemic Preparedness Innovations (CEPI) | Collaboration | United Kingdom |
| Industrial Biotechnology Innovation Centre | $14 | “Scotland has the natural resources and infrastructure that make it the perfect place for Industrial Biotechnology to thrive, bringing significant economic benefits. I am pleased to confirm that the Scottish Government, through our national agencies, is able to invest £11.1million to support IBioIC to drive forward Scotland’s Industrial Biotechnology sector.” | Scottish Government’s National Plan for Biotechnology | Fundraising | United Kingdom |
| Zosano Pharma Corporation | $14 | “This new financing partnership with Trinity provides support for commercial manufacture of M207 and is part of our planned technology transfer and scale up activities now underway,” said John Walker, chief executive officer and chairman of the board at Zosano. | Trinity Capital Investment | Equipment Lease Agreement | United States |
| General Practice Committee | $13 | The Winter Indemnity Scheme will be used to cover the costs of professional indemnity for the extra services provided by GPs, giving them the freedom to work extra sessions securely and without extra costs. | NHS England | Grants & Awards | United Kingdom |
| Arecor | $13 | Arecor’s next-generation diabetes product pipeline represents exciting new progress in the field of diabetes that will enable important new treatment regimens. Pipeline includes Proprietary formulations of insulin analogues and artificial pancreas development. | Calculus Capital | Fundraising | United Kingdom |
| MJ Freeway | $10 | “The industry is maturing rapidly and needs software that can handle increasing complexity, with state-of-the art functionality and data security,” said Jessica Billingsley, Co-Founder & CEO of MJ Freeway. | Batu Capital Investments | Series C Financing | United States |
| Antibe Therapeutics | $9.86 | ATB-346 is a novel anti-inflammatory drug, designed to spare the gastrointestinal (“GI”) tract of the ulcers and bleeding associated with NSAIDs. Antibe recently completed a Phase 2B study for ATB-346 that demonstrated unequivocal superiority in GI safety compared to naproxen, the most prescribed NSAID in US. | Kwang Dong Pharmaceutical | Licensing Agreement | Canada |
| CorFlow Therapeutics AG | $9.7 | The seed proceeds will finance the First-in-Man MOCA I (MVO with CoFITM System Assessment) clinical trial in Europe. The MOCA I trial is a safety and feasibility study of the newly developed CorFlow Controlled Flow Infusion (CoFITM) system which will be studied in 40 acute heart attack patients. | Undisclosed | Seed Funding | Switzerland |
| Titan Pharmaceuticals | $9.5 | Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology. The company's lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. | CIM Securities | IPO | United States |
| Tvardi Therapeutics | $9 | Series A funding is expected to enable the completion of ongoing Phase 1 studies for Tvardi’s lead compound TTI-101 in solid tumor cancers, and the completion of IND-enabling studies of a second product for use in non-cancer indications, including cachexia. | Undisclosed | Series A Financing | United States |
| Titan Pharmaceuticals | $6.70 | The fund has been granted for the development of a ProNeura™ based six-month implantable formulation of Nalmefene, an opioid antagonist, intended for the prevention of relapse to opioid addiction, following opioid detoxification. | National Institutes of Health's National Institute on Drug Abuse (NIDA) | Grants & Awards | United States |
| Elevian | $5.50 | Elevian's founders, working at Stanford and then Harvard, discovered the regenerative effects of young blood using a model called parabiosis. Elevian is on a path to make commercially viable drugs to treat major diseases of aging. Current areas of focus include Coronary Artery Disease, Alzheimer's Disease, Type 2 Diabetes and Sarcopenia (age-related muscle dysfunction). | Bold Capital | Seed Financing | United States |
| CEL-SCI Corporation | $5.4 | CEL-SCI's Phase 3 study is the largest Phase 3 study in the world for the treatment of head and neck cancer. Per the study's protocol, newly diagnosed patients with advanced primary squamous cell carcinoma are treated with the Multikine treatment regimen for 3 weeks prior to the Standard of Care (SOC) which involves surgery, chemotherapy and/or radiation. | Undisclosed | Fundraising | United States |
| Cadrock | $5 | Cadrock Pty Ltd owns an investigational prevention and treatment therapy for coronary artery disease (CAD). Cadrock data is backed by a clinical trial treating CAD as an infection with an antibiotic therapy in London, UK, which demonstrated a 36% reduction in Major Cardiac Events (MCEs) (STAMINA). | Undisclosed | Seed Investment | Australia |
| SAVSU Technologies | $5 | The 18-month purchase option provides BioLife, at its sole discretion, with the right to acquire the 56% of SAVSU not already owned. SAVSU will use the investment to scale up its operations and inventory to support increased demand for its evo®Dry Vapor Shippers and other precision temperature controlled shipping containers for cell and gene therapies. | BioLife Solutions | Fundraising | United States |
| Imperial College London, University College London | $5 | The money will be used to fund a virtual lab, led by Imperial, to apply Process Systems Engineering (PSE) methods to the pharmaceutical industry. PSE uses computer assisted methods and models to design, control and optimise processes. The approach has previously been used in the petrochemical, chemicals, and consumer goods industries. | Eli Lilly | Grants & Awards | United Kingdom |
| BloodCenter of Wisconsin | $5 | As part of the consortium, BloodCenter of Wisconsin's Blood Research Institute will receive approximately $5 million for its own Program for Career Development in Glycosciences. BloodCenter of Wisconsin Program for Career Development in Glycosciences (BloodCenter of Wisconsin, Medical College of Wisconsin, Virginia Commonwealth University and Roswell Park Cancer Institute) | National Heart, Lung and Blood Institute (NHLBI-NIH) | Grants & Awards | United States |
| Agenus | $5 | "This is the fourth antibody from our partnered programs that has advanced into clinical trials, once again proving our commitment to deliver on our existing partnerships," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. "In addition to this milestone, INCAGN2390 (anti-TIM-3) is expected to enter the clinic later this year, which would trigger an additional milestone payment to Agenus." | Incyte | Milestone Payment | United States |
| Merrimack Pharmaceuticals | $5 | "Since the start of the third quarter, Merrimack has received $38 million in non-dilutive capital, including two milestone payments from Shire totaling $23 million," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer of Merrimack. "We are pleased to further strengthen the Company's cash position as we continue advancing our wholly-owned clinical and preclinical pipeline." | Shire | Milestone Payment | United States |
| Virion Therapeutics | $5 | The Virion technology is built on a two-prong strategycombining the use of replication-incompetent chimpanzee adenoviral vectors with concomitant expression of glycoprotein D (gD), a novel checkpoint inhibitor that blocks suppression of T-cell production. ChiVax vaccines overcome a key limitation of human adenovirus-based vaccines, whose efficacy can be limited by pre-existing natural immunity against human adenoviruses. | Robin Hood Ventures | Series A Financing | United States |
| Forendo Pharma | $4.63 | The financing will enable Forendo Pharma to accelerate the development of its innovative women’s health portfolio. The Company also announces today that its lead program FOR-6219, a HSD17B1 inhibitor for the treatment of endometriosis , has commenced a Phase Ia study focusing on safety, tolerability and pharmacokinetics. | Vesalius Biocapital III Partners | Fundraising | Finland |
| Opiant Pharmaceuticals | $4.6 | “This $4.6 million BARDA contract, combined with the recently awarded $7.4 million grant we received from the National Institute on Drug Abuse (NIDA), further validates the potential of nasal nalmefene to be a vital life-saving product, both to reverse opioid overdose and to counter bioterrorism attacks. We expect to begin the pivotal pharmacokinetic study required for approval of OPNT003 by the U.S. Food and Drug Administration in 2019.” | Biomedical Advanced Research & Development Authority | Contract Agreement | United States |
| Hesperos | 4 | An 18-month $2 million Direct-to-Phase II SBIR grant from NCATS was awarded in 2016 to support development of advanced manufacturing techniques for a human-on-a-chip system being jointly developed by the University of Central Florida and Cornell. Hesperos was founded in 2014 to commercialize its novel human-on-a-chip technology, and prepare its systems for regulatory approval utilizing advanced PKPD modeling capabilities. | National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) | Grants & Awards | United States |
| Immusoft Corporation | 3.5 | Immusoft’s Phase II grant follows an earlier Phase I grant the company received to conduct studies to express IDUA in B cells using the Sleeping Beauty Transposon System, which delivers genes into cells without using a virus. As part of the Phase II, Immusoft will pursue a strategy for facilitating enhanced delivery across the blood-brain barrier and delivery of the IDUA enzyme. | National Institutes of Health (NIH) | Grants & Awards | United States |
| Tarsius Pharma | 3 | Tarsius is an Israel based early stage research and development company focusing on development of drug candidates in the field of Ophthalmology. Tarsius Pharma Ltd. develops a novel treatment for uveitis based on technology inspired by biomimetics. Biomimetic drugs are developed by emulating nature's models and processes to promote better medical treatment. | Sun Pharmaceutical Industries Ltd | Acquisition | Israel |
| Wacker Biotech GmbH (Wacker Chemie AG) | 2.94 | WACKER has enhanced its production facilities for biopharmaceuticals – also known as biologics – with new equipment. The suite enables independent cell-bank production and expands storage capacity for customer cell banks. The company invested €2.5 million in, among other things, a fully automated fermentation plant including a new bioreactor with a capacity of 350 liters, a new separator for efficiently isolating cells and a new GMP cell-bank suite. | Wacker Chemie AG | Manufacturing Investment | Germany |
| Carmel Biosciences | 2.7 | Nutriband will acquire the NDA and ownership rights to FDA approved Prexxartan™, the ownership and rights to develop and market Carmel's pipeline including CAR-509, CAR-510, CAR-511 and CAR-512 currently in Pre IND phase. | Nutriband | Acquisition | United States |
| OEB4 Facility | 2.65 | CatSci is currently investing in three new laboratories: an OEB4 facility, a compact large-scale laboratory and a dedicated analytical laboratory to support drug substance development and testing. This will enable the kilogram supply of non-GMP candidate drugs to customers for toxicity studies. | CatSci | Manufacturing Investment | United Kingdom |
| Prokaryotics | 2.3 | The two-year agreement will fund research by Prokaryotics on a natural product cell wall synthesis inhibitor targeting antimicrobial-resistant Neisseria gonorrhoeae. | National Institute of Allergy and Infectious Diseases (NIAID) | Grants & Awards | United States |
| Pherin Pharmaceuticals | 2.25 | The license agreement was signed for granting VistaGen exclusive worldwide rights to develop and commercialize PH94B nasal spray, a Phase 3-ready drug candidate for as-needed (PRN) treatment of Social Anxiety Disorder (SAD). | VistaGen Therapeutics | Licensing Agreement | United States |
| GI Dynamics | 2.2 | The funds raised under the first tranche of the Placement will be used by GI Dynamics to fund the continued development of EndoBarrier, to prepare for the U.S. pivotal trial of EndoBarrier | Undisclosed | Private Placement | United States |
| Arizona State University-Tempe Campus | 2 | phase 2 study of oral vancomycin for the treatment of primary sclerosing cholangitis – $2 million over four years | USFDA | Grants & Awards | United States |
| Cedars-Sinai Medical Center | 2 | phase 2 study of seliciclib for the treatment of Cushing disease | USFDA | Grants & Awards | United States |
| Oncolmmune | 2 | CD24Fc is OncoImmune’s lead compound which is designed to treat graft-versus-host disease, a rare condition in which cells in a bone marrow transplant view the recipient’s tissues as foreign and mount an attack. The company was awarded $2 million in order to continue its Phase IIb study program for CD24Fc. | USFDA | Grants & Awards | United States |
| University of North Carolina at Chapel Hill | 2 | phase 2 study of sildenafil for the prevention of bronchopulmonary dysplasia – $2 million over four years | USFDA | Grants & Awards | United States |
| RxHealth | 1.8 | Rx.Health's Bulk Prescription allows health care teams to prescribe digital therapeutics and patient-centered care plans to entire cohorts of patients through a single click. The funding will be used to diversify Rx.Health's client base and support its first-to-market Bulk Prescription™ digital therapeutics and patient engagement tool. | Mount Sinai Innovation Partners | Seed Financing | United States |
| Norman Lee, George Washington University | 1.8 | The grant was awarded to investigate the mechanisms driving dysregulation splicing factor expression. RNA splicing i.e. the editing of nascent precursor messenger RNA causes exons to join together to form mature mRNA, the different combinations of exons can lead to the formation of different functional proteins. | National Institutes of Health | Grants & Awards | United States |
| Alkeus Pharmaceuticals | 1.75 | Alkeus Pharmaceuticals was awarded $1.75 million to continue Phase II development of its Stargardt disease treatment, ALK-001. Stargardt disease is a form of inherited macular degeneration which affects just 30,000 individuals in the US. No treatments exist for this rare form of blinding eye disease, making the development of ALK-001 – a form of vitamin A – important for this underserved patient community. | USFDA | Grants & Awards | United States |
| George C. Cotzias Fellowship, APDA Centers for Advanced Research | 1.7 | Our funding support will help investigate new biomarkers of Parkinson’s disease, examine the scientific basis for gender differences in PD, and probe the differences in PD among people of varying ethnicities, among many other worthy projects that will have an impact on the future of PD research” - Rebecca Gilbert, MD, PhD, Vice President and Chief Scientific Officer, APDA. | American Parkinson Disease Association (APDA) | Grants & Awards | United States |
| Auctus Biologics (Ichor Therapeutics) | 1.5 | The company will develop RPtag, a hyper-stable antibody mimetic scaffold to take on conventional clinical antibody therapy as an orally bioavailable formulation. | Undisclosed | Seed Funding | United States |
| Emory University | 1.5 | For phase 1/ 2 study of Ad/PNP fludarabine for the treatment of head and neck squamous cell carcinoma | USFDA | Grants & Awards | United States |
| Fibrocell Science | 1.4 | The Grant will enable Fibrocell’s continued clinical development of FCX-007, the Company’s gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a devastating, rare skin blistering disease with high mortality. | FDA's Office of Orphan Products Development (OOPD) | Grants & Awards | United States |
| Patagonia Pharmaceuticals | 1.5 | This non-dilutive funding will help support our clinical development of PAT-001, a proprietary topical formulation of isotretinoin in development for Congenital Ichthyosis. | USFDA | Grants & Awards | United States |
| Protagonist Therapeutics | 1.45 | The objective of the SBIR-funded research is to develop methods for characterizing in vivo target engagement, including pharmacokinetic and pharmacodynamic methods to characterize PTG-300 interactions, effects on pathway and disease biomarkers, and effects in pre-clinical disease models. | National Institutes of Health - National Heart, Lung and Blood Institute | Grants & Awards | United States |
| University of Minnesota | 1.4 | phase 2a study of subcutaneous hydrocortisone infusion pump for the treatment of congenital adrenal hyperplasia – $1.4 million over 3years. | USFDA | Grants & Awards | United States |
| General Hospital Corporation | 1.4 | phase 2 study of kisspeptin for the treatment of dopamine agonist intolerant hyperprolactinemia – $1.4 million over four years | USFDA | Grants & Awards | United States |
| Medicines Discovery Catapult | 1.31 | The partners (OptibriumTM, Intellegens and Medicines Discovery Catapult) are developing an AI platform that drug discovery companies – particularly UK SMEs – can use under licence. | Innovate UK | Grants & Awards | United Kingdom |
| India Globalization Capital | 1 | India Globalization Capital (IGC Pharma) is a company engaged in the development and commercialization of cannabinoid-based alternative therapies for medical conditions including Alzheimer’s disease, Parkinson’s disease, and pain, announced that it raised $1.0 million in a private placement of restricted shares. The net proceeds from the offering are for marketing and working capital associated with the commercialization of Hyalolextm. | Bradbury Investment Fund (Bradbury Group) | Private Placement | United States |
| Johns Hopkins University | 0.75 | phase 1/2 study of CD8-reduced T cells for the treatment of myelodysplastic syndrome or acute myeloid leukemia – $750,000 over three years | USFDA | Grants & Awards | United States |
| Cobra Biologics, Centre for Process Innovation, GE Healthcare Life Sciences | 0.744 | The three-way partnership, funded by a £570K Innovate UK grant, aims to increase the robustness and reduce costs for the manufacturing of adeno-associated virus (AAV) vectors, a delivery vehicle used for emerging gene therapy treatments. | Innovate UK | Grants & Awards | United Kingdom |
| Knopp Biosciences | 0.693 | Knopp is directing its Kv7 potassium channel activator program to the discovery and development of best-in-class small-molecule drug candidates, consistent with the goals of the NIH BPN. The BPN, part of the NIH Blueprint for Neuroscience Research, is a collaboration of NIH Institutes and Centers that supports research on the nervous system with the goal of developing new neurotherapeutic drugs. | National Institutes of Health Blueprint Neurotherapeutics Network (BPN) | Grants & Awards | United States |
| Phoenix PharmaLabs | 0.187 | The grant will fund additional studies to determine if PPL-103 has potential to be used for treatment of cocaine addiction. Results from earlier in vivo studies conducted by Phoenix with NIDA support have demonstrated that PPL-103 is effective for opioid addiction therapy. | National Institutes of Health (NIH)/National Institute for Drug Abuse (NIDA) | Grants & Awards | United States |
| Dr. Aline Betancourt (Tulane University) | Undisclosed | Acquisition of the Patent Portfolio will enable SanBio to expand its development pipeline into areas of inflammatory disorders and cancer targeted by SB623. SanBio is currently conducting phase 2 clinical trials of regenerative cell medicine SB623 which consists of mesenchymal stem cells derived from adult bone marrow that undergo a genetic modification. | SanBio Group | Patent Portfolio Acquisition | United States |
| Vertex Pharmaceuticals (Europe) Limited | Undisclosed | This agreement means lumacaftor/ivacaftor will be listed on the Pharmaceutical Benefits Scheme (PBS) from 1 October and follows a positive recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC). A pathway to access for future Vertex CF medicine, tezacaftor/ivacaftor, has been established as part of this process. | Australian Government | Reimbursement Agreement | United Kingdom |
| Mahad API Manufacturing facility | Undisclosed | Olon S.p.A., CDMO acquired a local generics chemical operations API manufacturing facility in Mahad, India, as part of a continuing expansion of its global footprint. As part of the asset purchase agreement, the parties have committed to sign a long-term supply contract to guarantee continuous supply of Sandoz products manufactured in Mahad. | Olon S.p.A. | Acquisition | India |
| Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO) | Undisclosed | With state-of-the art facilities of 1,300m2 (12,000ft2) at the Campus Berlin-Buch, EPO offers, in particular, a comprehensive range of well characterized syngeneic tumor models, Patient Derived Xenograft (PDX) models and humanized tumor models. Citoxlab carries out studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis/biomarkers. | Citoxlab | Partnership | Germany |
| OS Therapies | Undisclosed | OS Therapies, in collaboration with the Children’s Oncology Group (COG)1, will be responsible for the conduct and funding of a clinical study evaluating ADXS-HER2 in recurrent, completely resected osteosarcoma. | Advaxis | Licensing Agreement | United States |
| Tsinghua University | Undisclosed | Scientists will work in the Boehringer Ingelheim-Tsinghua University Joint Research Center for Immuno-Infection to harness the mechanisms of immune modulation to combat infectious diseases. | Boehringer Ingelheim | Collaboration | China |
| La Jolla Institute for Allergy and Immunology | Undisclosed | Turnstone will utilize La Jolla Institute’s proprietary neoantigen identification methodology to select personalized neoantigens to target with its proprietary viral technologies for the development of new cancer immunotherapies. | Turnstone Biologics | Licensing Agreement | United States |
| Trianni | Undisclosed | This license agreement grants Gilead the use of the Trianni's transgenic human monoclonal antibody discovery platform to support the company’s drug discovery efforts. | Gilead Sciences | Licensing Agreement | United States |
| Center for Medicinal Cannabis Research (CMCR) at UC San Diego School of Medicine | Undisclosed | Insys has ongoing clinical trials of CBD oral solution as an investigational treatment for childhood absence epilepsy (Phase 2), infantile spasms (Phase 3) and Prader-Willi syndrome (Phase 2). The two organizations announced plans for a CMCR study of CBD from INSYS in pediatric patients with autism. | INSYS Therapeutics | Collaboration Expansion | United States |
| Clinerion | Undisclosed | The companies will collaborate using Clinerion’s intelligent, patented Patient Network Explorer platform and Patient iP’s proprietary daTAscape asset to better target clinical trial sites and accelerate trial enrollment on a global scale. | Patient iP | Partnership | Switzerland |
| Sartorius Stedim Biotech | Undisclosed | Through the partnership, Sartorius Stedim Biotech and Repligen will further collaborate to equip SSB’s recently launched ambr® 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo® hollow fiber filter technology. The bioreactor system will be sold by SSB as a complete single-use assembly. | Repligen Corporation | Collaboration | Germany |
| Blood Centers of America | Undisclosed | The agreement will enable deeper support of joint research and product development and provide valuable expertise needed for commercial therapies. Working together, the organizations will focus on removing barriers to the supply of critical raw materials needed for pre-clinical research and for clinical manufacturing of cell-based therapies. | Key Biologics | Partnership | United States |
| Celltheon Corporation | Undisclosed | This partnership aligns Pall Biotech equipment and consumables with the Celltheon SMART™ Expression Platform to deliver integrated manufacturing solutions for customers developing biotherapeutics. It is part of Pall’s strategic approach to forming key partnerships that help enable better, safer and faster biologic production. | Pall Biotech (Pall Corporation) | Partnership | United States |
| Plasticell Ltd | Undisclosed | Plasticell will deploy its combinatorial stem cell screening platform, CombiCult®, to develop technologies for the conversion of pluripotent stem cells into platelets that promote tissue recovery and regeneration. | Ministry of Defence (MoD) | Contract Agreement | United Kingdom |
| IRBM | Undisclosed | For this project, IRBM will be applying its expertise in phage display peptide library design and screening and in chemical peptide synthesis and optimization, to identify potential peptide leads for a specific Merck target. | Merck & Co. | Collaboration | Italy |
| Ossianix | Undisclosed | Ossianix will use its patented single domain VNAR antibodies to deliver a predefined number of therapeutic agents of Novo Nordisk. Novo Nordisk will be responsible for the development and commercialization of the therapeutic products. | Novo Nordisk | Research and Option Agreement | United Kingdom |
| University of Pennsylvania | Undisclosed | The agreements between Precision and Penn include a Research, Collaboration and License Agreement (RCLA) with funding provided to Penn and a license to certain technology invented under the RCLA. The collaboration will include three gene knock-out programs and up to three gene knock-in or gene repair programs. | Precision BioSciences | Licensing Agreement | United States |
| Nevada Center for Behavioral Health (NCBH) | Undisclosed | The company's collaboration with Nevada Center for Behavioral Health (NCBH) aims to evaluate a medication-assisted treatment (MAT) program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients within the State of Nevada criminal justice system. | Titan Pharmaceuticals | Collaboration | United States |
| Enamine | Undisclosed | The collaboration provides StarDrop™ users with easy access to EnamineStore and further extends the wealth of information available to users through StarDrop and its capabilities for small molecule design, optimisation and data analysis in drug discovery. | Optibrium | Collaboration | Ukraine |
| Pall Corporation | Undisclosed | This partnership aligns Pall Biotech equipment and consumables with the Celltheon SMART™ Expression Platform to deliver integrated manufacturing solutions for customers developing biotherapeutics. | Celltheon Corporation | Partnership | United States |
| Repligen Corporation | Undisclosed | Sartorius Stedim Biotech and Repligen will collaborate to equip SSB’s recently launched ambr® 250ht perfusion single-use mini bioreactor system with Repligen’s KrosFlo® hollow fiber filter technology. The bioreactor system will be sold by SSB as a complete single-use assembly. | Sartorius Stedim Biotech | Partnership | United States |
| Checkmate Pharmaceuticals | Undisclosed | The agreement entails the evaluation of CMP-001, a TLR9 agonist, in combination with avelumab*, a human anti-PD-L1 antibody. The collaboration will evaluate the safety and effectiveness of CMP-001 administered in combination with avelumab in patients with advanced squamous cell cancer of the head and neck (SCCHN) resistant to a prior PD-1/PD-L1 inhibitor. | Merck KGaA, Pfizer | Clinical Collaboration | United States |
| Cook Biotech | Undisclosed | Both companies will collaborate in the advancement of AcuityBio’s ABC103 lead product for lung cancer, which will utilize Cook Biotech’s proprietary extracellular matrix (ECM) technology. | AcuityBio | Collaboration | United States |
| AstraZeneca AB | Undisclosed | The Agreement is for the development and commercialization rights to AZD3241, an oral myeloperoxidase (MPO) inhibitor that AstraZeneca progressed through Phase 2 clinical trials. Biohaven plans to conduct a Phase 3 clinical trial of this product candidate for the treatment of multiple system atrophy (MSA) | Biohaven Pharmaceutical Holding Company Ltd. | Commercialization Agreement | Sweden |
| NHS England | Undisclosed | The landmark deal means young people with a form of leukaemia are set to receive CAR-T (a chimeric antigen receptor T-cell) therapy within weeks, after NICE also green-lighted the treatment for entry into the reformed NHS Cancer Drugs Fund. The Tisagenlecleucel form of CAR-T, also known as Kymriah, is the first in a wave of treatments in a new era of personalised medicine and part of the NHS’s long term plan to upgrade cancer services. | Novartis | Commercialization Agreement | United Kingdom |
| ZeOmega | Undisclosed | EmpiRx Health is revolutionizing the pharmacy benefits arena as a risk-bearing PBM that offers best-in-class pharmacy care management. EmpiRx will deploy the case management capabilities within Jiva—including identification and stratification of patients with complex case management needs. | EmpiRx Health | Collaboration | United States |
| AMRI | Undisclosed | The alliance will promote Metrion's electrophysiology and ion channel screening expertise to global pharmaceutical and biotechnology clients. As part of the agreement, AMRI will be able to offer its customers access to Metrion's broad portfolio of assay tools and technologies for ion channel screening, cardiac safety profiling and neuroscience applications. | Metrion Biosciences Ltd | Collaboration | United Kingdom |
| Nemours / Alfred I. duPont Hospital for Children | Undisclosed | The collaboration focuses on to initiate a clinical trial in children with Fragile X Syndrome. The planned protocol for the pilot open-label trial will dose Fragile X patients from 8 to less than 18 years of age, using a dosing regimen similar to that being tested in AD patients. | Neurotrope | Clinical Collaboration | United States |
| Secarna Pharmaceuticals | Undisclosed | Secarna's proprietary antisense oligonucleotide platform LNAplusTM to be combined with Firebrand Therapeutics' scientifically leading research into mechanisms of cancer metastasis | Firebrand Therapeutics | Co-Development Agreement | Germany |
| KK Women's and Children's Hospital | Undisclosed | The partnership provides Blockchain-based healthcare services power improvements to training for hospital staff and care management for expecting and neonatal mothers | Everest | Partnership | Singapore |
| Nestlé Skin Health/ Galderma | Undisclosed | The GALDERMA R&D site in Sophia-Antipolis which opened in 2006 is the world’s largest research and development center focused on medical and cosmetic solutions for the skin. The new capabilities will strengthen NUVISAN’S core service lines in Bioanalysis, Clinical Trial Supplies and Pharmaceutical Analytics as well as enhancing the portfolio by adding GMP-API synthesis and formulation capability for prescription drugs and cosmetics. | Nuvisan Pharma Services | Takeover | Switzerland |
| Suono Bio | Undisclosed | Suono Bio leverages the technology developed by Institute Professor Robert Langer at the Massachusetts Institute of Technology to facilitate rapid, local administration of therapeutics to treat inflammatory-mediated diseases. | FUJIFILM Holdings Corporation | Fundraising | United States |
| CrystalGenomics | Undisclosed | Apsen will secure exclusive rights for the Brazilian market to sell and market Acelex 2mg, a novel COX-2 inhibitor developed by CrystalGenomics for the treatment of osteoarthritis. CrystalGenomics will exclusively supply Apsen with the finished drug product at an agreed upon transfer price. | Apsen Farmacêutica | Export Agreement | South Korea |
| XoNovo | Undisclosed | The partnership aims to generate crucial information concerning XoNovo’s lead compound, XN001, a patented new chemical entity (NCE); an autophagy modulator for the treatment of neurodegenerative diseases. According to the agreement, Inoviem will apply its expertise and cutting-edge technological solutions to isolate and identify XN001’s therapeutic targets and elucidate its mode of action. | Inoviem Scientific | Partnership | Israel |
| Moffitt Cancer Center | Undisclosed | As part of the collaboration, Atara will gain access to novel CAR T targeting and co?stimulation domains designed to improve T cell proliferation and enhance persistence. This agreement furthers the Company’s strategy to develop next generation engineered CAR T immunotherapies across multiple therapeutic areas and leverage the Company’s off-the-shelf, allogeneic T-cell immunotherapy platform. | Atara Biotherapeutics | Collaboration | United States |
| Leukocare AG | Undisclosed | LEUKOCARE will work closely with Xellia's team of product development experts and apply its proprietary SPS® (Stabilizing and Protecting Solutions) formulation technology platform. Xellia will have access to LEUKOCARE´s proprietary SPS® formulation technology platform to be used for its antibiotic and antifungal product portfolio. | Xellia Pharmaceuticals | Partnership | Germany |
| BeiGene, Ltd. | Undisclosed | The aim of the global clinical collaboration agreement is to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene’s investigational RAF dimer inhibitor, lifirafenib (BGB-283) and SpringWorks Therapeutics’ investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors. | SpringWorks Therapeutics | Clinical Collaboration | China |
| Cedars-Sinai Medical Center | Undisclosed | The collaboration is for the evaluation of the efficacy and safety of SYN-010- modified-release reformulation of lovastatin lactone, which is exclusively licensed to Synthetic Biology by Cedars-Sinai Medical Center. SYN-010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). | Synthetic Biologics | Clinical Collaboration | United States |
| Pliant Therapeutics | Undisclosed | The collaboration aims to accelerate the discovery of potential disease targets for gastrointestinal fibrosis. The collaborators will utilize primary human cells, tissues and organ culture systems as well as novel animal models of intestinal fibrosis to identify and validate new druggable targets for fibrosis of the gut that results from conditions such as Crohn’s disease. | Cleveland Clinic | Collaboration | United States |
| Managed Health Care Associates, Inc. (MHA) | Undisclosed | Going forward, SoftWriters, which develops innovative pharmacy management software solutions for long-term care pharmacies, will be responsible for the support, delivery and further development of RxPertise, the acclaimed Medication Regimen Review (MRR) software application for consultant pharmacists specializing in long-term care. | SoftWriters | Partnership | United States |
| GNS Healthcare | Undisclosed | The goal of the collaboration is to better understand the factors that drive and predict a patient's response to Amgen's metastatic CRC treatment, panitumumab. GNS will leverage its powerful causal AI platform to create causal models from the CALGB 80405 (Alliance) phase III clinical trial data in combination with Amgen's PEAK trial data. | Amgen, Alliance for Clinical Trials in Oncology | Partnership | United States |
| Medicines360 | Undisclosed | Through this alliance, Medicines360, a nonprofit, and Afaxys will co-promote LILETTA to the 340B-participating public health sector, helping to expand access to the full range of FDA-approved contraception for women. LILETTA is a sterile, levonorgestrel-releasing intrauterine system indicated for prevention of pregnancy for up to 4 years. | Afaxys Pharma | Collaboration | United States |
| AG Mednet | Undisclosed | GCTP works collaboratively with clients to determine an approach that best suits their unique needs and handles development of the endpoint process from start to finish. | Global Clinical Trial Partners | Partnership | United Kingdom |
| sanaplasma AG | Undisclosed | The acquisition of sanaplasma AG is expected to increase Shire’s access to plasma in the longer term and add to its European plasma collection network, complementing existing core capabilities in plasma supply and manufacturing. | Shire plc | Acquisition | Ireland |
| Walgreens | Undisclosed | AUVI-Q is a prescription medicine approved by the FDA to treat emergency allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions. Through the AUVI-Q AffordAbility program provided by kaléo, eligible patients with commercial insurance, even those with high-deductible plans, can obtain AUVI-Q at no cost. | Kaléo | Partnership | United States |
| TGaS® Advisors | Undisclosed | Trinity will add TGaS’s unique benchmarking products to its real-world evidence and primary market research capabilities to power its strategic advisory offerings in corporate and product strategy, launch readiness, pricing and market access, and health economics. | Trinity Partners | Acquisition | United States |
| GlaxoSmithKline plc | Undisclosed | Ezogabine, also known as retigabine, is the only anti-epileptic drug previously approved by the FDA with a mechanism of action that potentiates Kv7-mediated potassium current. GlaxoSmithKline (GSK) marketed ezogabine in various jurisdictions – as Potiga® in the U.S. and Trobalt™ in Europe – but withdrew the drug from the market worldwide in June 2017 citing commercial reasons. | Xenon Pharmaceuticals | Pipeline Transfer Agreement | United Kingdom |
| CYTOO | Undisclosed | Initially, the aim of the research collaboration will be to modify CYTOO' s existing MyoScreenTM platform to enable its potential use as a Duchenne muscular dystrophy (DMD) target discovery platform. | Pfizer | Research and Option Agreement | France |
| Evotec AG | Undisclosed | Evotec and Celgene will leverage Evotec’s Panomics platform in order to identify drug targets which are traditionally difficult to track. Evotec’s Panomics platform applies in particular high-end proteomics and transcriptomics at industrial scale to profile and select promising drug candidates on the basis of comprehensive cell biological profiles. | Celgene Corporation | Partnership | Germany |
| Amedica Corporation | Undisclosed | CTL Medical will acquire all of Amedica’s commercial spine business for total consideration of up to $10 million. The deal will make CTL Medical the world's exclusive provider of silicon nitride spine products and give it unique access to markets like Brazil and Australia, and widen its European footprint, further strengthening its position as a global leader serving the spine industry. | CTL Medical Corporation | Asset Acquisition | United States |
| Ieso Digital Health | Undisclosed | The aim of this program is to demonstrate that those diabetes patients with mental health issues can be successfully identified and their depression or anxiety treated, through an integrated, holistic approach – ultimately leading to better and more effective management of their whole condition. | Roche Diabetes Care | Collaboration | United Kingdom |
| Bloom Science | Undisclosed | Under the agreement, Biose industrie will develop a manufacturing process at its industry leading development and manufacturing facility in France. Bloom Science is rapidly advancing the science of translating the ketogenic diet into a new class of neuroprotective medicines for patients with epilepsy and other challenging neurological conditions. | Biose industrie | Manufacturing Agreement | United States |
| BDD Pharma | Undisclosed | The agreement, which includes an upfront payment, milestones and future royalties, relates to the development of CTx-1301 and CTx-1302 for the treatment of ADHD. BDD's proprietary OralogiK™ technology provides unrivalled control of drug release in vivo - delivery at the right place and the right time. | Cingulate Therapeutics | Licensing Agreement | Scotland |
| PharmaMar | Undisclosed | This was previously announced as one of the key elements of the strategy for the merger between Pharma Mar and Zeltia S.A. (regulatory announcement of 2 Dec 2014) and in other subsequent communications. | Undisclosed | IPO | Spain |
| Dyadic International | Undisclosed | Sanofi will fund the collaborative research which will utilize the proprietary and patented C1 Gene Expression Platform Technology to express multiple genes for vaccine and drug applications. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosim | Sanofi-Aventis Deutschland GmbH (Sanofi Group) | Collaboration | United States |
| A. Menarini Diagnostics S.r.l. (Menarini Group) | Undisclosed | LabSat™ Frozen is an ultra-rapid automated tissue staining solution performing immunohistochemistry (IHC) assays in a few minutes. Thanks to this breakthrough technology, patients will be able to benefit from a faster, better and more personalized treatment starting in the operating room. | Lunaphore Technologies SA | Partnership | Italy |
| Centre for the Commercialization of Antibodies and Biologics (CCAB), University of Toronto | Undisclosed | The agreement provides Triumvira with an exclusive license for antibodies discovered at the University of Toronto (U of T) on specified therapeutic targets. CCAB is the assigned agent for the U of T for the commercialization of a large portfolio of human antibodies. U of T will receive up-front fees, milestone payments and royalty payments on net sales of products on three therapeutic targets: BCMA, ROR1 and one undisclosed target. | Triumvira Immunologics | Licensing Agreement | Canada |
| AltiBio | Undisclosed | AltiBio is developing two molecules for undisclosed rare diseases. The company has conducted successful proof of concept studies and has filed patent applications to support its therapeutic strategies for three projects: ATB223, ATB224, and ATB338. | BioMarin | Series A Financing | United States |
| Inhibrx | Undisclosed | The agreement showcases the expansive biologics pipeline of Inhibrx and the world leading technical expertise and capabilities of WuXi Biologics. Inhibrx will exclusively use WuXi Biologics for GMP manufacturing of its human biologic therapeutics for all projects to be initiated within next 3 years which Inhibrx plans to first initiate clinical trials outside of China. | WuXi Biologics | Partnership | United States |
| Mundipharma Southeast Asia | Undisclosed | The companies have signed an agreement for the marketing, sales and distribution of well-known pain medicine brands Voltaren® (diclofenac sodium) and Cataflam® (diclofenac potassium) in Malaysia, Thailand, and the Philippines. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, swelling (inflammation), and joint stiffness caused by arthritis. | Novartis | Partnership | Singapore |
| Haplogen Bioscience GmbH, Cyclenium Pharma | Undisclosed | The project exploits Cyclenium’s proprietary CMRT™ (“smart”) drug discovery technology together with Haplogen’s exquisite expertise in flaviviral biology to identify new agents for therapeutic and prophylactic use against all major pathogenic organisms from this family, including dengue, Zika, West Nile, Japanese encephalitis and yellow fever viruses. Haplogen Bioscience will continue to thoroughly characterize the therapeutic molecules. The partners intend to jointly develop and commercialize t | National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) | Grants & Awards | Austria |
| ATP Science Pty Ltd | Undisclosed | Both ATP Science and Griffith University (GU) will work together to develop a novel plant extraction process and analyte detection methodology. ATP Science believes that the research collaboration with Griffith University will specifically yield new knowledge in novel plant extracts that can be incorporated into new and existing ATP Science supplement products to enhance the nutritional value delivered to clients and end-users of the products. | Griffith Institute | Collaboration | Australia |
| Sherpa Clinical Packaging | Undisclosed | The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position as a leader in outsourced clinical trial support services. Sherpa’s core services include primary and secondary packaging and labeling for Phase I-IV studies, distribution, storage and returns. | PCI Pharma Services | Acquisition | United States |
| Foundation Medicine | Undisclosed | The agreement is for the development, regulatory support and commercialization of companion diagnostics (CDx), with an initial focus on CDx development for pemigatinib (INCB54828), Incyte’s selective FGFR1/2/3 inhibitor, in patients with cholangiocarcinoma. The initial CDx is expected to be included in the detection of activating FGFR2 translocations. | Incyte | Commercialization Agreement | United States |
| Glenmark Pharmaceuticals S.A. | Undisclosed | Glenmark's immuno-oncology pipeline currently includes three bispecific monoclonal antibody (bsAb) candidates being studied in a wide range of tumor types. GBR 1302, a HER2xCD3 bsAb and GBR 1342, a CD38XCD3 bsAb are currently in Phase 1; and GBR 1372, an EGFRxCD3 bsAb, is in preclinical development. | Mitra Biotech | Partnership | Switzerland |
| Amygdala Neurosciences | Undisclosed | NIAAA will fund and conduct a Phase 2, human laboratory study of ANS-6637 for the treatment of alcohol use disorder. ANS-6637 is a selective ALDH2 Inhibitor that prevents pathophysiologic dopamine surge and associated craving without changes to basal dopamine. | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Clinical Collaboration | United States |
| Systech | Undisclosed | This partnership provides a revolutionary blockchain-enabled solution for the pharmaceutical industry that leverages FarmaTrust's blockchain and AI technologies. The Systech platform will now provide a solution that goes beyond today's current compliance, traceability, anti-counterfeit and product safety solutions, enabling clients to ensure product authenticity from the manufacturing floor to a patient's hands. | FarmaTrust | Partnership | United States |
| Entitled Health on the Map | Undisclosed | The creation of the platform is the result of Abbott's research "Patient Empowerment - Importance and Challenges", made with 960 people from all regions of Brazil, diagnosed with diabetes and hypertension. | Abbott | Platform Launch | Brazil |
| Samsung BioLogics | Undisclosed | Immunomedics' Chief Technology Officer said " The partnership will ensure that we have sufficient long-term supply of our lead antibody-drug conjugate, sacituzumab govitecan, as we advance it into additional patient segments and earlier lines of breast and urothelial cancers, as well as broadening into other cancer indications and expanding the company’s ex-US geographic footprint. | Immunomedics | Manufacturing Partnership | South Korea |
| Drug Substance Manufacturing Facility | Undisclosed | Two Russian-Chinese joint ventures will be established with the main purpose of development, manufacturing, authorization, and marketing of at least six BIOCAD products used in advanced therapy of cancer and autoimmune diseases (chronic lymphpatic leukemia, colorectal cancer, lung cancer, breast cancer, psoriasis, ankylosing spondylitis, etc.). | BIOCAD, Shanghai Pharmaceuticals Holding | Joint Venture | China |
| One Nucleus | Undisclosed | This exclusive partnership will give One Nucleus members immediate access to thousands of CROs, CMOs, academic institutes, core labs and a global community of scientists from the world’s top R&D organizations. | Science Exchange | Collaboration | United Kingdom |
| Spotlyte Digital Hub | Undisclosed | Beyond the editorial, Spotlyte will provide access to a team of trained specialists ready to offer real-time support and chat directly with anyone considering medical aesthetic treatments, as well as help connect readers to local licensed providers. | Allergan plc | Platform Launch | Ireland |
| RadiaDyne | Undisclosed | This transaction expands AngioDynamics’ growing Oncology business by adding RadiaDyne’s early-stage, proprietary OARtrac® real-time radiation dose monitoring platform and other market-leading oncology solutions, including the IsoLoc®/ImmobiLoc® and Alatus® balloon stabilizing technologies. | AngioDynamics | Acquisition | United States |
| Ron Keizer, PhD | Undisclosed | Pirana is a flexible, extendible pharmacometrics workbench that provides modelers with structure, tools and a graphical user interface to facilitate the iterative processes used to create pharmacometric models and perform simulations. | Certara | Asset Acquisition | United States |
| Novacyt (Primerdesign) | Undisclosed | Primerdesign and AMI can provide a full suite of assay development services from probe designs, through to assay optimisation, regulatory and manufacturing of SNP microarrays. The microarray based molecular diagnostic tests developed under this partnership will play a crucial role in the early diagnosis, and improve patient management. | Applied Microarrays | Partnership | France |
| Primary Care Global Business Unit; China & Emerging Markets | Undisclosed | The company will create a new Primary Care GBU that combines the product portfolios of Sanofi's existing Diabetes and Cardiovascular (DCV) GBU with Established Products. Sanofi is creating a second new global business unit called China & Emerging Markets to be led by Olivier Charmeil, currently head of the GEM GBU. This newly-formed business will focus on growth opportunities in China which is Sanofi's second largest market after the United States. | Sanofi | Business Reorganization | France |
| Brain Biomarker Solutions Gothenburg AB | Undisclosed | The objective of the research collaboration is to develop new and improved diagnostic methods for Alzheimer's disease by identifying and measuring new biomarkers in cerebrospinal fluid (CSF) and blood. Support for this hypothesis is that BioArctic's drug candidate BAN2401, which is directed towards amyloid beta protofibrils, recently in a large Phase 2b study showed significant clinical efficacy. | BioArctic AB | Research Agreement | Sweden |
| Nashville Facility | Undisclosed | PMI Bio's protein sciences express and purify proteins and develop assays around protein targets using NMR, SPR, crystallography, ITC, (TR)FRET, and DSF to name a few. | PMI BioPharma Solutions | Manufacturing Investment | United States |
| Relief Therapeutics Holding SA | Undisclosed | The Agreement will follow a four-year development plan including pre-clinical and clinical milestones with the goal of reducing allergenicity or even preventing food (particularly milk) allergy in humans. | Health and Happiness (H&H) Hong Kong Limited | Licensing Agreement | Switzerland |
| Jackson Laboratory, Azitra | Undisclosed | The goal of the program is to identify bioactive compounds produced by Staphylococcus epidermidis (S. epidermidis) that can inhibit Staphylococcus aureus (S. aureus) and ultimately treat skin infections. | Department of Defense | Grants & Awards | United States |
| J. David Gladstone Institutes | Undisclosed | Fate Therapeutics has exclusively licensed intellectual property from the J. David Gladstone Institutes that covers the generation of induced pluripotent stem cells using CRISPR-mediated gene activation. This new approach for inducing pluripotency uses CRISPR to directly target a specific location of the genome and activate endogenous gene expression, and does not rely on established methods of cellular reprogramming that require the transduction of multiple transcription factors. | Fate Therapeutics | Licensing Agreement | United States |
| Horizon Discovery Group | Undisclosed | AstraZeneca has been evaluating Horizon’s Edit-R human whole genome crRNA library for gene knockout since late 2017, and will soon add the Company’s platform of arrayed synthetic crRNA libraries for CRISPR-mediated transcriptional activation (CRISPRa). | AstraZeneca | Collaboration | United Kingdom |
| Genecast Biotechnology Co. Ltd. | Undisclosed | Under the partnership, Genecast will develop a cancer diagnosis system and kit specifically targeting colorectal cancer. Genecast will also develop a cancer diagnosis system and kit aimed at lung cancer based on Illumina's NGS technology. | Illumina | Partnership | China |
| Evotec AG | Undisclosed | Through the research collaboration, the companies will develop first-in-class therapeutics through a novel approach to disrupt cell signalling, that is expected to deliver highly potent and durable treatments for debilitating dermatology diseases such as psoriasis and atopic dermatitis. The collaboration combines Evotec’s cutting-edge drug discovery and pre-clinical development platforms with Almirall’s leading expertise in dermatology diseases. | Almirall, S.A. | Collaboration | Germany |
| Agawam, MA facility | Undisclosed | Avista Pharma is investing to upgrade its Agawam, MA facility, increasing its analytical chemistry footprint while expanding its compendial and raw material testing capabilities. | Avista Pharma Solutions | Manufacturing Investment | United States |
| CSP Technologies | Undisclosed | Activ-BlisterTM solutions is among CSP’s latest innovations, designed to actively control the internal atmosphere/headspace of individual blister cavities without the use of purging, allowing for improved stability and enhanced shelf life. | PCI Pharma Services | Collaboration | United States |
| Fate Therapeutics | Undisclosed | Using Fate Therapeutics’ proprietary induced pluripotent stem cell (iPSC) product platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality. | Ono Pharmaceutical | Collaboration | United States |
| Houston Methodist Research Institute | Undisclosed | The agreement will additionally enable VGXI’s parent company, GeneOne Life Science, to leverage the design capabilities provided by Houston Methodist and the research team led by John Cooke, MD, PhD for development of new RNA vaccines and therapies. | GeneOne Life Science | Licensing Agreement | United States |
| Datavant | Undisclosed | “Partnering with Datavant will allow PAREXEL to optimize clinical studies and real-world evidence generation using techniques that represent a true inflection point in how information will be consolidated in our industry.” | PAREXEL International Corporation | Partnership | Switzerland |
| CSP Technologies | Undisclosed | CSP Technologies, Inc. is a world leader in moisture protection and gas scavenging solutions, and has developed several gas scavenging solutions to protect sensitive products in a variety of industries, including pharmaceuticals, drug delivery systems/medical devices, and diagnostics. | PCI Pharma Services | Collaboration | United States |
| GE Healthcare Life Sciences | Undisclosed | The KUBio will be located in Guangzhou, the capital city of Guangdong Province, China, where an increasing number of biotech firms are establishing operations. BeiGene is already using GE Healthcare’s FlexFactory, its existing manufacturing plant in Suzhou, China to manufacture mAbs for clinical trials. | BeiGene | Manufacturing Partnership | United States |
| Valeo Pharma | Undisclosed | Utrogestan is indicated for luteal phase support during in-vitro fertilization (IVF) cycles. "As Utrogestan® has already been granted marketing approval by Health Canada, we are on track for a 2019 product launch," added Marc Leger, Chief Commercial Officer. | Besins Healthcare | Commercialization Agreement | Canada |
| MorphoSys | Undisclosed | The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies’ pipelines. | LEO Pharma | Alliance | Germany |
| Pandion Therapeutics | Undisclosed | Just will provide Pandion with a suite of services leveraging Just’s fully integrated technology platform, J.DESIGN™. The services include cell line development, process development, and Phase 1 cGMP clinical manufacturing of a selected drug candidate to expedite Pandion’s IND filing by the end of 2019. | Just Biotherapeutics | Manufacturing Agreement | United States |
| Neurimmune | Undisclosed | Neurimmune conducts research to generate and validate human-derived monoclonal antibodies using its proprietary Reverse Translational MedicineTM (RTMTM) technology platform. Ono will be responsible for worldwide development and marketing of products derived from this collaboration. Neurimmune is eligible to receive research fees, success-based milestones on the research and development progress, as well as royalties on product sales. | Ono Pharmaceutical | Milestone Payment | Switzerland |
| Emory University School of Medicine | Undisclosed | Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidates for atherosclerosis. Celltrion will have a preferential right to acquire a license for inventions resulting from the agreement. | Celltrion | ‘Incubation’ Agreement | United States |
| Tmunity Therapeutics | Undisclosed | Under the agreement Abzena will humanize monoclonal antibodies using its Composite Human Antibody™ technology. This technology combines humanization and deimmunisation technologies to generate fully-humanized therapeutic antibodies devoid of CD4+ T cell epitopes. | Abzena | Licensing Agreement | United Kingdom |
| University of Jaén | Undisclosed | The goal for the program is to synthesize and develop a backup clinical compound to the Company's lead product candidate, PRP. The development of the backup compound will be used for treating patients with limited therapeutic options for the treatment of solid tumors, | Propanc Biopharma | Collaboration | Spain |
| APEIRON Biologics AG | Undisclosed | The two companies will perform drug discovery activities to optimize and develop novel small molecules addressing immune checkpoints, important gatekeepers in cancer immunity. All molecules deriving from this collaboration are proprietary to APEIRON and will strengthen APEIRON’s development pipeline. | Lead Discovery Center GmbH | Collaboration | Austria |
| Servier's Hu-PreciMED project | Undisclosed | The project was jointly launched by Oncodesign, Servier and Intersystems. With more than 45 innovative digital and medical companies already participating, Hu-PreciMED aims to bring together all public and private players working in the field of precision medicine and connect them efficiently to medical data from patients. | Medicen Paris Region | Partnership | France |
| Academic Health Science Network | Undisclosed | The collaborative projects will address the new national priority areas of the AHSN Network. The Greater Manchester Pharmaceutical Industry Partnership has resulted in the progression of three substantial projects in Hepatitis C, COPD and mental health in its first year of operation. | Association of the British Pharmaceutical Industry | Partnership | United Kingdom |
| Oswaldo Cruz Foundation ‘Fiocruz’ | Undisclosed | The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region. | Emergex Vaccines Holding | Memorandum of Understanding | Brazil |
| HealthCare Partners (DaVita) | Undisclosed | Both organizations agreed to working on an integrated delivery system and offer seamless patient care management through open lines of communication and care coordination between HealthCare Partners physicians and the KPC Health system of hospitals where they practice. | KPC Health | Partnership | United States |
| Vaximm AG | Undisclosed | VAXIMM will collaborate with CMS, which will have the full rights in China and other Asian countries (excluding Japan) to VAXIMM's existing programs, enabling the development and commercialization of VAXIMM's pipeline of oral cancer immunotherapy candidates in the region. In parallel with the agreement, CMS will make an equity investment in VAXIMM, as part of VAXIMM's current Series B financing. | China Medical System Holdings Limited | Commercialization Agreement | Switzerland |
| Amprologix, University of Plymouth | Undisclosed | Amprologix aims to develop and bring to market novel antimicrobials to tackle antibiotic resistance. Amprologix will develop and commercialise the work of Professor Mathew Upton, Chief Scientific Officer at Ingenza. Epidermicin can now be produced in a GMP compliant microbe, suitable for industrial scale-up using synthetic biology methods developed by Ingenza. | Ingenza | Spin-out | United Kingdom |
| Oxford Genetics | Undisclosed | The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and Europe, has been extended to include the Asia Pacific (APAC) region, to support the company’s international growth following demand for the service quadrupling in 2018. | ERS Genomics | License Extension | United Kingdom |
| Tencent Holdings | Undisclosed | The collaboration will focus on heart disease and give patients access to Tencent’s health services, including reminders to take their medication, Bertrand Bodson, Novartis’s digital strategy leader since January, said Wednesday in an interview. Medicine-tracking systems will help patients avoid counterfeit products, according to Novartis. | Novartis China | Partnership | China |
| Daiichi Sankyo Company | Undisclosed | Under the terms of the agreement, Daiichi Sankyo will conduct a two-part phase 1b multicenter, open-label study to determine the safety, tolerability and dose of DS-8201 in combination with KEYTRUDA and evaluate efficacy of the combination in patients with HER2 expressing advanced/metastatic breast cancer and patients with HER2 expressing or HER2 mutant advanced/metastatic NSCLC. | Merck & Co. | Clinical Collaboration | Japan |
| Tessa Therapeutics | Undisclosed | The goal of the partnership is to accelerate the preclinical development of CAR-expressing Virus-Specific T cells (VSTs) leading to clinical testing in the near future. | St. Jude Children’s Research Hospital | Collaboration | Singapore |
| Invicro (Konica Minolta Company) | Undisclosed | Enigma will hold the various commercial and distribution licenses and be responsible for development and global tracer access whereas Invicro will focus on informatics solutions for better interpretation of this cutting-edge biomarker technology. Use of this biomarker platform is an additional approach to supporting development of disease-modifying therapies for neurodegenerative disorders. | Enigma Biomedical | Memorandum of Understanding | United States |
| CareNet, Inc., Medical Incubator Japan K.K, Vital KSK Holdings, Inc. and Astem Inc. | Undisclosed | In the SB623 development program targeting chronic motor deficit from ischemic stroke in the US, phase 2b clinical trials are currently underway. SanBio is currently preparing for the development of SB623 with an aim of launching the product targeting chronic motor deficit from ischemic stroke in Japan ahead of anywhere else in the world. | SanBio | Joint Venture | Japan |
| SignalPath Research Consortium | Undisclosed | The SignalPath Research Consortium is a rapidly growing network of sophisticated clinical trials sites connected via a technical foundation. New York Cancer and Blood Specialists is a leading example; this innovative community-based oncology practice is deploying SignalPath's novel operational, financial, oversight and study start-up software to support the conduct of research at their sites. | SignalPath | Consortium | United States |
| MEBIAS Discovery | Undisclosed | MEBIAS Discovery will use the NIDA funds to complete preclinical pharmacological and pharmaceutical profiling. Once milestones outlined in the grant are met, MEBIAS is eligible for continued funding from NIDA to progress the lead compound into Phase 1 clinical studies. | National Institute of Drug Abuse (NIDA) | Grants & Awards | United States |
| NextWave Pharmaceuticals (Pfizer) | Undisclosed | The acquisition further expands Tris' portfolio of products for the treatment of patients with ADHD. The agreement includes the acquisition of Quillivant XR, the first and only marketed extended-release oral liquid methylphenidate, and QuilliChew ER, the first and only extended-release methylphenidate chewable tablet, both of which are central nervous system (CNS) stimulants approved for the treatment of ADHD. | Tris Pharma | Acquisition | United States |
| Santen Pharmaceutical | Undisclosed | PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify macrocyclic/constrained peptides against multiple ophthalmic disease targets of interest selected by Santen, and to optimize hit peptides into therapeutic peptides products for such indications. | PeptiDream | Development Agreement Amendment | Japan |
| Enesi Pharma Ltd | Undisclosed | Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, announces it has entered a Cooperative Research and Development Agreement (CRADA) with the Walter Reed Army Institute of Research (WRAIR), a United States Department of Defense Laboratory, regarding Shigella vaccine development. | Walter Reed Army Institute of Research (WRAIR) | Research and Development Agreement | United Kingdom |
| Astellas Pharma | Undisclosed | The leading development product using i-DPS technology, APS001F, a recombinant Bifidobacterium to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is under a phase 1 clinical trial in the U.S. | Anaeropharma Science | Collaboration | Japan |
| I-Mab Biopharma | Undisclosed | Through the extension of existing collaboration agreement, I-Mab Biopharma licensed proprietary WuXiBody™ Platform to develop three bispecific antibodies. WuXi Biologics will also be the exclusive partner to develop and manufacture these bispecifics. | WuXi Biologics | Licensing Agreement | China |
| Agilent Technologies | Undisclosed | Under the terms of the agreement, Agilent will manufacture and supply Cancer Genetics with the custom probe for use in the Company’s FISH-based HPV-Associated Cancer Test (FHACT®). Additionally, Cancer Genetics’ plans to outlicense the probes through domestic and international distribution channels, with such licensors having the ability to purchase probes manufactured by Agilent. | Cancer Genetics | Supply Agreement | United States |
| Fullerton Healthcare Corporation Limited | Undisclosed | The Partnership to fully integrate online and offline healthcare services in the region by combining the complementary strengths of the two partners. The new HMO platform will provide WeDoctor's approximately 160 million registered users in China with access to Fullerton Health's extensive network of over 500 healthcare facilities and over 8,000 network healthcare providers. | We Doctor Holdings Limited | Partnership | Hong Kong |
| Brill Pharma Laboratories | Undisclosed | The formulation, marketed in the United States as Acuicyn™ Eyelid and Eyelash Hygiene solution, is a safe and efficacious method to keep areas around the eye and eyelids/eyelashes clean. The Spanish/Portuguese formulation, to be branded as Ocudox™, will be marketed as a pre-surgical antimicrobial for use in eye surgery, intraoculus injections and any eye manipulation that requires sterile conditions. | Sonoma Pharmaceuticals | Licensing Agreement | Spain |
| ACT Genomics | Undisclosed | ACTG's flagship NGS panel, ACTOnco®+, investigates 440 cancer-related genes by incorporating a signaling pathway design. ACTOnco®+ provides optimal treatment suggestion to clinicians, including targeted therapies, hormonal therapies, chemotherapies, and immunotherapies, for all solid tumor types. | CLSA Capital Partners | Equity Investment | Japan |
| Urgo Medical North America | Undisclosed | The newly formed entity created today, September 26th, takes the name Urgo Medical North America. Its headquarters will remain in Fort Worth, Texas, under the leadership of the former management team. With a yearly turnover of approximately $20M, Urgo Medical North America will operate in the USA and Canada with ambitions to become a global leading player in the world's largest advanced wound care market of North America. | URGO Medical, SteadMed Medical | Merger Agreement | United States |
| Global Antibiotic Research & Development Partnership | Undisclosed | Agreement focuses on further enhancing generic antibiotics and increasing access for children in low- and middle-income countries (LMICs); Development will target heat-stable, pediatric formulations such as dispersible tablets against bacterial infections – a leading cause of death in under-fives; and Partnership will leverage knowledge and share expertise between Sandoz, the Novartis generics division, and GARDP. | Sandoz (Novartis) | Partnership | Switzerland |
| Oricula Therapeutics | Undisclosed | ORC-13361 is a new chemical entity (NCE) currently being investigated for the prevention of ototoxicity which results from treatment with aminoglycoside antibiotics. A Phase I clinical trial to evaluate safety, tolerability and pharmacokinetics of ORC-13361 is currently ongoing. | Decibel Therapeutics | Licensing Agreement | United States |
| Mikart | Undisclosed | Mikart’s broad range of capabilities includes formulation development, clinical trial supplies, regulatory filing support, analytical services, clinical manufacturing, commercial manufacturing, and packaging while emphasizing a quality-first approach and best-in-class manufacturing and regulatory capabilities. . | Nautic Partners | Acquisition | United States |
| UPMC Health Plan | Undisclosed | The goal of the contract is to align the incentives of the manufacturer, Boehringer Ingelheim, with the UPMC Health Plan, and will link reimbursement of the drug to costs associated with clinical outcomes in the real-world population. In a first-of-its-kind contract, reimbursement for the medication will be linked to total costs of care for all people with diabetes treated. | Boehringer Ingelheim | Contract Agreement | United States |
| Aetna's Medicare Part D business unit | Undisclosed | Aetna announced an agreement to divest all of Aetna’s standalone Medicare Part D business to a subsidiary of WellCare Health Plans, Inc. (WellCare). The divestiture is subject to the completion of CVS Health’s proposed acquisition of Aetna, regulatory approvals and other customary closing conditions. | WellCare Health Plans | Divestment | United States |
| Pharmacia Corporation | Undisclosed | This protease platform is a novel combination of enzymes first isolated and developed by Pharmacia Corporation in Sweden. It has been tested in over 551 patients and has demonstrated safety and efficacy for multiple indications including wound healing, thrombogenic disease and anti-viral applications. | Marizyme | Asset Purchase Agreement | Sweden |
| Dova Pharmaceuticals | Undisclosed | As part of the co-promotion arrangement, Salix intends to deploy approximately 100 sales specialists who will promote DOPTELET to gastroenterology healthcare professionals. DOPTELET is designed to mimic the effects of TPO, the primary regulator of normal platelet production. | Salix Pharmaceuticals | Co-Promotion Agreement | United States |
| Luitpold Pharmaceuticals (Daiichi Sankyo Company) | Undisclosed | LYNCH Biologics will market the GEM 21S product together with a suite of complementary regenerative biologic products direct to oral surgeons, periodontists and implant dentists through its cranio-maxillofacial division. | LYNCH Biologics | Marketing Agreement | Japan |
